|
Poveda-Garcia A, Ruiz E, Moreno MJ, Espanol I, Sanchez-Salinas A, Garcia-Hernandez AM, Blanquer M, Martinez I, Sanchez-Villalobos M, Garcia Garay MC, Salido E, Heredia A, Navarro-Almenzar B, Monserrat J, Sanchez-Salas JA, Martinez-Mellado AJ, Minguela A, Campillo JA, Lopez-Hernandez R, Galian JA, Moraleda JM, Roldan V, Cabanas V. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis. Bone Marrow Transplant. 2024 Nov;59(11):1625-1627. doi: 10.1038/s41409-024-02404-1. Epub 2024 Aug 26. No abstract available. PubMed PMID: 39187602.
AÑO: 2024; IF: 5.2
|
39187602
|
Sun R., Moraleda J.M., Wei L.J. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma. JAMA Oncology. 16 May 2024. 10:674. 10.1001/jamaoncol.2024.0116
AÑO: 2024; IF: 20.1
|
|
Beltran A, Sanchez-Villalobos M, Salido E, Alguero C, Campos E, Perez-Oliva AB, Blanquer M, Moraleda JM. Flow Cytometry as a New Accessible Method to Evaluate Diagnostic Osmotic Changes in Patients with Red Blood Cell Membrane Defects. Biomedicines. 2024 Jul 19;12(7):1607. doi: 10.3390/biomedicines12071607. PubMed PMID: 39062184; PubMed Central PMCID: PMC11274888.
AÑO: 2024; IF: 3.9
|
|
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, de Cerio AL, Cabanas V, Lopez-Munoz N, Rodriguez-Otero P, Reguera JL, Moreno DF, Martinez-Cibrian N, Lopez-Corral L, Perez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Penataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodriguez-Lobato LG, Battram AM, Gonzalez MS, Sanchez-Salinas A, Gonzalez-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernandez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15;30(10):2085-2096. doi: 10.1158/1078-0432.CCR-23-3759. PubMed PMID: 38466644.
AÑO: 2024; IF: 10.2
|
|
Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera JL, Lopez-Corral L, Martin-Antonio B, Zabaleta A, Inoges S, Varea S, Rosinol L, Lopez-Diaz de Cerio A, Tovar N, Jimenez R, Lopez-Parra M, Rodriguez-Lobato LG, Sanchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Perez-Simon JA, Paiva B, Prosper F, Saez-Penataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernandez de Larrea C. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. PubMed PMID: 37414060.
AÑO: 2023; IF: 41.6
|